| Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the S wedish A cute L eukemia R egistry E Hulegårdh, C Nilsson, V Lazarevic, H Garelius, P Antunovic, ... American journal of hematology 90 (3), 208-214, 2015 | 286 | 2015 |
| Complete long‐term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer J Lehmann, L Franzaring, J Thüroff, S Wellek, M Stöckle BJU international 97 (1), 42-47, 2006 | 124 | 2006 |
| Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of≥ 120 g/L with darbepoetin alfa±filgrastim or erythrocyte … H Nilsson‐Ehle, G Birgegård, J Samuelsson, P Antunovic, J Astermark, ... European journal of haematology 87 (3), 244-252, 2011 | 79 | 2011 |
| Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities L Möllgård, L Saft, MB Treppendahl, I Dybedal, JM Nørgaard, J Astermark, ... Haematologica 96 (7), 963, 2011 | 68 | 2011 |
| Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low-and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial M Tobiasson, I Dybedahl, MS Holm, M Karimi, L Brandefors, H Garelius, ... Blood Cancer Journal 4 (3), e189-e189, 2014 | 63 | 2014 |
| Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013 S Lehmann, S Deneberg, P Antunovic, Å Rangert-Derolf, H Garelius, ... Leukemia 31 (6), 1457-1459, 2017 | 56 | 2017 |
| Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register D Moreno Berggren, Y Folkvaljon, M Engvall, J Sundberg, M Lambe, ... British journal of haematology 181 (5), 614-627, 2018 | 46 | 2018 |
| Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes L de Swart, C Reiniers, T Bagguley, C van Marrewijk, D Bowen, ... haematologica 103 (1), 69, 2018 | 45 | 2018 |
| Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden G Juliusson, J Abrahamsson, V Lazarevic, P Antunovic, Å Derolf, ... Leukemia 31 (3), 728-731, 2017 | 44 | 2017 |
| Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome HKG Garelius, WT Johnston, AG Smith, S Park, L De Swart, P Fenaux, ... Journal of internal medicine 281 (3), 284-299, 2017 | 42 | 2017 |
| A pilot phase I dose finding safety study of the thrombopoietin‐receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine T Svensson, O Chowdhury, H Garelius, F Lorenz, L Saft, SE Jacobsen, ... European journal of haematology 93 (5), 439-445, 2014 | 40 | 2014 |
| Patient‐tailored analysis of minimal residual disease in acute myeloid leukemia using next‐generation sequencing EBR Malmberg, S Ståhlman, A Rehammar, T Samuelsson, SJ Alm, ... European journal of haematology 98 (1), 26-37, 2017 | 35 | 2017 |
| Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting C Nilsson, E Hulegårdh, H Garelius, L Möllgård, M Brune, A Wahlin, ... Biology of blood and marrow transplantation 25 (9), 1770-1778, 2019 | 33 | 2019 |
| Survival in adult acute lymphoblastic leukaemia (ALL): a report from the Swedish ALL Registry E Lennmyr, K Karlsson, L Ahlberg, H Garelius, E Hulegårdh, AS Izarra, ... European journal of haematology 103 (2), 88-98, 2019 | 30 | 2019 |
| Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome M Hoeks, T Bagguley, C van Marrewijk, A Smith, D Bowen, D Culligan, ... Leukemia 35 (6), 1745-1750, 2021 | 18 | 2021 |
| Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications C Nilsson, F Linde, E Hulegårdh, H Garelius, V Lazarevic, P Antunovic, ... Haematologica 108 (4), 1015, 2023 | 16 | 2023 |
| Development of a core outcome set for myelodysplastic syndromes–a Delphi study from the EUMDS Registry Group U Rochau, I Stojkov, A Conrads‐Frank, HH Borba, KA Koinig, M Arvandi, ... British Journal of Haematology 191 (3), 405-417, 2020 | 14 | 2020 |
| Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study D Moreno Berggren, M Kjellander, E Backlund, M Engvall, H Garelius, ... British Journal of Haematology 192 (3), 474-483, 2021 | 13 | 2021 |
| Randomized phase II study of azacitidine±lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del (5q) B Rasmussen, G Göhring, E Bernard, L Nilsson, M Tobiasson, ... Leukemia 36 (5), 1436-1439, 2022 | 12 | 2022 |
| Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective T De Witte, L Malcovati, P Fenaux, D Bowen, A Symeonidis, M Mittelman, ... haematologica 105 (11), 2516, 2020 | 12 | 2020 |
